$3.64
0.28% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Stock price

$3.64
-0.47 11.44% 1M
+0.83 29.54% 6M
+1.14 45.60% YTD
+1.80 97.83% 1Y
+0.28 8.33% 3Y
+2.13 141.06% 5Y
-13.60 78.89% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.01 0.28%
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Key metrics

Market capitalization $689.75m
Enterprise Value $568.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 84.38
P/S ratio (TTM) P/S ratio 102.34
P/B ratio (TTM) P/B ratio 6.45
Revenue growth (TTM) Revenue growth -69.69%
Revenue (TTM) Revenue $6.74m
EBIT (operating result TTM) EBIT $-78.55m
Free Cash Flow (TTM) Free Cash Flow $-70.63m
Cash position $127.79m
EPS (TTM) EPS $-0.43
P/E forward negative
P/S forward 111.27
EV/Sales forward 91.69
Short interest 4.38%
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Arbutus Biopharma Corporation forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
80%
Hold
20%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6.74 6.74
70% 70%
100%
- Direct Costs 1.41 1.41
4% 4%
21%
5.34 5.34
74% 74%
79%
- Selling and Administrative Expenses 20 20
4% 4%
292%
- Research and Development Expense 63 63
21% 21%
932%
-77 -77
0% 0%
-1,145%
- Depreciation and Amortization 1.41 1.41
4% 4%
21%
EBIT (Operating Income) EBIT -79 -79
0% 0%
-1,165%
Net Profit -77 -77
2% 2%
-1,138%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Neutral
GlobeNewsWire
about 10 hours ago
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Neutral
GlobeNewsWire
one day ago
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following...
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Michael McElhaugh
Employees 73
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today